IL1B and cardiac hypertrophy: Studies employing pharmacologic blockade or ribonucleic acid (RNA) interference targeting NLRP3, as well as the inhibition of IL-1β with neutralizing antibodies, have demonstrated mitigated pressure overload-induced myocardial hypertrophy [30].